Press releases - Medizinonline

Skyrizi® approved in PsA

Effective treatment option for metastatic NSCLC with METex14 skipping mutation is now eligible for health insurance coverage

Venetoclax receives approval for AML

BOTOX® newly approved for the treatment of focal spasticity of any etiology.

RINVOQ® for atopic dermatitis to be approved by health insurers as of 2022

Input your search keywords and press Enter.